Novo Nordisk A/S (NYSE:NVO) Stock Price Up 4% – Still a Buy?

Novo Nordisk A/S (NYSE:NVO)’s stock price rose 4% during trading on Tuesday . The company traded as high as $36.75 and last traded at $36.7070. Approximately 18,830,779 shares traded hands during trading, a decline of 22% from the average daily volume of 24,192,109 shares. The stock had previously closed at $35.29.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Launched multi-month, discounted Wegovy subscription plans for U.S. self-pay patients to deliver lower, predictable monthly prices and improve affordability vs. competitors — seen as a retention/access play to protect share versus Eli Lilly. Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US
• Positive Sentiment: Announced an established share repurchase programme (part of up to DKK 15bn over 12 months) — buybacks support EPS and act as a shareholder-return lever amid revenue pressure. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Reported completion of a key China pharmacokinetics/safety study for a new obesity and diabetes candidate — clinical progress de-risks development timelines and expands future market opportunity in China. Novo Nordisk Advances New Obesity and Diabetes Drug With Key China Study Completion
• Positive Sentiment: Expanded commercial partnerships that increase affordable access (Weight Watchers preferred Wegovy pricing via NovoCare) — could support volume growth among self-pay and program members. Weight Watchers Announces Best-in-Market Self-Pay Wegovy Pricing…
• Neutral Sentiment: Continuing to deploy AI across R&D and development workflows (alongside peers like Lilly) — potentially a long-term efficiency and speed advantage, but not an immediate revenue driver. Lilly and Novo Show How AI Is Rewiring Big Pharma
• Negative Sentiment: Cut prices of Ozempic and Wegovy in India (reductions up to ~36–48%) to better compete as local generics arrive — margin and pricing pressure in emerging markets is a near-term revenue headwind. Novo Nordisk further slashes prices of Ozempic, Wegovy in India…
• Negative Sentiment: Announced layoffs at the Bloomington, Indiana manufacturing site (about 400 workers) — indicates cost actions and operational adjustments in response to shifting demand and competitive dynamics. Novo Nordisk to lay off 400 Bloomington employees
• Negative Sentiment: Ongoing investor concern and negative coverage about market share loss to Eli Lilly and weak recent share performance (analyst/press skepticism and bearish commentary). This feeds volatility and explains part of the stock’s recent weakness despite corrective commercial steps. NVO Stock “Nothing Short of Disaster,” Wegovy Subscription Program Lifts Shares

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NVO. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, February 24th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, March 18th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Finally, Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Four analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Price Performance

The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $163.90 billion, a price-to-earnings ratio of 10.58, a P/E/G ratio of 8.52 and a beta of 0.74. The business’s 50 day simple moving average is $45.38 and its 200-day simple moving average is $50.29.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to analysts’ expectations of $11.97 billion. On average, research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 23.63%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of large investors have recently modified their holdings of NVO. Capital International Investors lifted its position in shares of Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after buying an additional 6,092,192 shares during the last quarter. Loomis Sayles & Co. L P grew its position in Novo Nordisk A/S by 6.0% in the fourth quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock valued at $871,848,000 after acquiring an additional 969,916 shares during the last quarter. Franklin Resources Inc. raised its stake in Novo Nordisk A/S by 5.1% during the fourth quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after acquiring an additional 717,719 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Novo Nordisk A/S by 3.5% in the fourth quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after acquiring an additional 428,660 shares during the last quarter. Finally, Folketrygdfondet lifted its holdings in shares of Novo Nordisk A/S by 1.2% in the third quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after acquiring an additional 117,370 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.